AU782370B2 - Nucleic acid delivery system - Google Patents

Nucleic acid delivery system Download PDF

Info

Publication number
AU782370B2
AU782370B2 AU18621/01A AU1862101A AU782370B2 AU 782370 B2 AU782370 B2 AU 782370B2 AU 18621/01 A AU18621/01 A AU 18621/01A AU 1862101 A AU1862101 A AU 1862101A AU 782370 B2 AU782370 B2 AU 782370B2
Authority
AU
Australia
Prior art keywords
composition
nucleic acid
particles
carrier particles
polymeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU18621/01A
Other languages
English (en)
Other versions
AU1862101A (en
Inventor
Per Artursson
Holly Guan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9904475A external-priority patent/SE9904475D0/xx
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU1862101A publication Critical patent/AU1862101A/en
Assigned to MERCK PATENT GMBH reassignment MERCK PATENT GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: PHARMACONCEPTS AB
Application granted granted Critical
Publication of AU782370B2 publication Critical patent/AU782370B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU18621/01A 1999-12-08 2000-12-07 Nucleic acid delivery system Ceased AU782370B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9904475A SE9904475D0 (sv) 1999-12-08 1999-12-08 Nucleic acid delivery system
SE9904475 1999-12-08
US17130799P 1999-12-21 1999-12-21
US60/171307 1999-12-21
PCT/EP2000/012339 WO2001041810A2 (en) 1999-12-08 2000-12-07 Nucleic acid delivery system

Publications (2)

Publication Number Publication Date
AU1862101A AU1862101A (en) 2001-06-18
AU782370B2 true AU782370B2 (en) 2005-07-21

Family

ID=26663687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18621/01A Ceased AU782370B2 (en) 1999-12-08 2000-12-07 Nucleic acid delivery system

Country Status (6)

Country Link
EP (1) EP1235597A2 (ja)
JP (1) JP2003516365A (ja)
AU (1) AU782370B2 (ja)
CA (1) CA2393526A1 (ja)
MX (1) MXPA02005697A (ja)
WO (1) WO2001041810A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3895737A1 (en) 2007-06-29 2021-10-20 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance
JP2020193164A (ja) * 2019-05-28 2020-12-03 佐々木　均 経肺投与用薬物送達体およびこれを含む経肺投与用薬剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199903A (ja) * 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEE REFERENCES OF WO 2001/041810 *

Also Published As

Publication number Publication date
JP2003516365A (ja) 2003-05-13
EP1235597A2 (en) 2002-09-04
CA2393526A1 (en) 2001-06-14
WO2001041810A3 (en) 2002-04-25
WO2001041810A2 (en) 2001-06-14
MXPA02005697A (es) 2004-09-10
AU1862101A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
US20030166594A1 (en) Nucleic acid delivery system
Bernocchi et al. Nasal nanovaccines
Li et al. Nonviral gene therapy
AU720989B2 (en) Gene therapy delivery system for targeting to endothelia
Davis Non-viral gene delivery systems
Almeida et al. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly (l‐lactic acid) microspheres in rats, rabbits and guinea‐pigs
Wiethoff et al. Barriers to nonviral gene delivery
US6677313B1 (en) Method for gene therapy using nucleic acid loaded polymeric microparticles
Shilpa et al. Niosomes as vesicular carriers for delivery of proteins and biologicals
US7384923B2 (en) Liposomes
JP2003535122A (ja) 生物活性物質のための送達システム
US20070116767A1 (en) Chitosan-microparticles for ifn gene delivery
IL144084A (en) Therapeutic calcium phosphate particles and methods of manufacture and use
Howard et al. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines
US20020068090A1 (en) Calcium phosphate particles as mucosal adjuvants
JP2005511644A (ja) 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法
Munir et al. Spray drying: Inhalable powders for pulmonary gene therapy
Gebrekidan et al. Formulation and in vitro transfection efficiency of poly (D, L-lactideco-glycolide) microspheres containing plasmid DNA for gene delivery
Perrie et al. Recent developments in particulate-based vaccines
AU782370B2 (en) Nucleic acid delivery system
WO1999061063A1 (fr) Preparations geniques stables
Howard et al. The development of polyplex-based DNA vaccines
Bisht et al. Intraperitoneal administration of calcium phosphate nanoparticles encapsulating pSVβgal elicits immune response to encoded protein
Khatri et al. Potential of nanocarriers in genetic immunization
Du et al. Preparation and Characterization of DNA Liposomes Vaccine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 44, PAGE(S) 9693-9696 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 18621/01

PC1 Assignment before grant (sect. 113)

Owner name: MERCK PATENT GMBH

Free format text: THE FORMER OWNER WAS: PHARMACONCEPTS AB